In the summer of 2021, over 200 biopharma executives were surveyed about their changing approaches to building biologic drug development pipelines. This executive summary presents the findings from this outreach.
To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).
Ashfield Engage, part of UDG Healthcare plc, today announced that it has been selected by U.S.-based Pacira BioSciences Inc. to provide strategic commercialization services for the company’s non-opioid pain management products in select European countries. Pacira has partnered with Ashfield Engage to develop a commercial strategy and deliver outsourced operations in numerous European countries, including the UK, Germany, Sweden, Austria, the Netherlands and Finland.
An ever-shifting sales landscape calls for a nimble, responsive sales approach – one often problematic for the behemoth infrastructures of many large pharmaceutical organizations and the experience level of emerging biotechnology firms. As a result, commercial services partners offer a stronger than ever value proposition to the industry.
